Zeist, Netherlands, April 5, 2024 — We’re proud to announce the appointment of Ricard Quingles Blasi as our new Chief Business Officer (CBO). With over 25 years of dynamic leadership experience, Ricard Quingles Blasi brings a wealth of strate...
On the 27th of June, we will organise the webinar: 'Clinical Consequences of the New MASLD Nomenclature' with guest speaker Prof. Maja Thiele.During this webinar, our speaker and hosts will dive into the following topics:Is the MASLD nom...
Commentary by Dr. Marco Alings, MD PhD, Amphia Ziekenhuis, Breda; WCN, Utrecht; Scientific Officer at Julius ClinicalThe estimated prevalence of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in the adult population is 31% ...
Utrecht, The Netherlands, 05-02-2024GRIPonMASH, a newly founded consortium consisting of 27 European institutions and companies, has bundled resources to bring about a transformational change in the detection and treatment of Metabolic Dysfunc...
On March 12th, we organised the webinar: Getting GRIP on MASH after LITMUSDuring this webinar, our speaker and hosts explored the following topics:The usefulness of noninvasive diagnostic methods depends on the prevalence of the disease ...
Julius Clinical Research Receives Growth Investment from Ampersand Capital Partners Partnership will further expand Julius’ clinical trial services capabilities to advance new therapeutics.Zeist, Netherlands, November 28, 2023 -- Julius Cli...
We are excited to announce that Julius Clinical has a brand-new look and website as part of the ongoing evolution of our company’s brand.Why? Ever since its foundation in 2008, Julius Clinical has been based on a unique triangle of scientif...
On December 12th, we organised the webinar:Revolutionizing Kidney Failure Treatment: Clinical Impact and Lessons Learned from the CONVINCE Clinical TrialDuring this webinar, our speaker and hosts explored the following topics:Study d...
We are proud to announce the publication of our latest research article titled "A global survey of health care workers' awareness of non‐alcoholic fatty liver disease: The AwareNASH survey." This article summarizes the findings of the AwareNASH ...
Last Friday, the results of the CONVINCE trial were published in the prestigious New England Journal of Medicine. We are thrilled to announce that the CONVINCE study has shown that the use of high-dose hemodiafiltration led to a remarkable 23% low...
"*" indicates required fields
"*" indicates required fields
